2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Phospholipase

Phospholipase

Phospholipase

Related Products

PDF 1.13 MB

Phospholipase is a member of a very complex group of enzymes that break down phospholipids into fatty acids and other compounds. Phospholipases are defined by the enzymatic reaction they catalyze. The classes are phospholipase A, which has members A1 and A2; phospholipase B, which can carry out the reactions of both A1 and A2; phospholipase C; and phospholipase D.

Phospholipase A2 (PLA2) catalyses the hydrolysis of the sn-2 position of glycerophospholipids to yield fatty acids and lysophospholipids. Phospholipase C (PLC) converts phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). DAG and IP3 each control diverse cellular processes and are also substrates for synthesis of other important signaling molecules. PLC is thus central to many important interlocking regulatory networks. Phospholipase D (PLD) is an essential enzyme responsible for the production of the lipid second messenger phosphatidic acid (PA), which is involved in fundamental cellular processes, including membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival.

Phospholipase Isoform Specific Products:

Phospholipase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-103097
    ST271
    		Inhibitor 98.00%
    ST271 is a potent inhibitor of protein tyrosine kinase (PTK), inhibits phospholipase D activation stimulated by fMet-Leu-Phe and PAF, with IC50s of 6.7 and 9 μM, respectively.
    ST271
  • HY-118994
    ARN19874
    		Inhibitor 99.54%
    ARN19874 is a selective, reversible uncompetitive N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) activity inhibitor with an IC50 of ~34 μM.
    ARN19874
  • HY-134082A
    (Z)-Oleyloxyethyl phosphorylcholine
    		Inhibitor
    (Z)-Oleyloxyethyl phosphorylcholine ((Z)-OPC) is an isomer of Oleyloxyethyl phosphorylcholine (OPC). Oleyloxyethyl phosphorylcholine is an inhibitor of secreted Phospholipase A2 (sPLA2), which is involved in the biosynthesis of proinflammatory lipid media. Oleyloxyethyl phosphorylcholine can be used to study inflammatory diseases. Oleyloxyethyl phosphorylcholine also modified the red blood membrane and was used to bind the oxygen-carrying liquid perfluorocarbons as an antivenom agent to reduce toxin-induced hemolysis.
    (Z)-Oleyloxyethyl phosphorylcholine
  • HY-19757
    Lp-PLA2-IN-1
    		Inhibitor 99.18%
    Lp-PLA2-IN-1 is a potent Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2-IN-1 has the potential for atherosclerosis, Alzheimer's disease research.
    Lp-PLA2-IN-1
  • HY-115768A
    Compound 48/80 (trimer)
    Compound 48/80 (trimer) is a trimer of Compound 48/80 (HY-115768). Compound 48/80 is widely used in animal and tissue models as a "selective" mast cell activator.
    Compound 48/80 (trimer)
  • HY-148388
    N-Stearoylsphingomyelin
    		Inhibitor 98.60%
    N-Stearoylsphingomyelin (N-Stearoyl-D-sphingomyelin) is a sphingolipid, which can inhibit Phospholipase Cδ1 (PLCδ1).
    N-Stearoylsphingomyelin
  • HY-135799
    WH-15
    		99.51%
    WH-15 is a fluorogenic PLC reporter with Km value of 49; 30, 86.1 µM for PLC-γ1, PLC-δ1, PLC-β2, respectively. WH-15 can be cleaved in a cascade reaction to generate fluorescent 6-aminoquinoline. WH-15 can be used to respond to imaging PLC activity in live cells.
    WH-15
  • HY-144636
    Atg4B-IN-2
    		Inhibitor 98.03%
    Atg4B-IN-2 is a potent competitive Atg4B inhibitor with Ki value of 3.1 μM, also possesses declining PLA2 inhibitory potency, IC50s of 11 μM and 3.5 μM for Atg4B and PLA2, respectively. Atg4B-IN-2 enhances the anticancer activity of anti-castration-resistant prostate cancer agents via autophagy inhibition.
    Atg4B-IN-2
  • HY-124700
    LYPLAL1-IN-1
    		Inhibitor ≥99.0%
    LYPLAL1-IN-1 (Compound 11) is an selective covalent small-molecule inhibitor of Lysophospholipase-like 1 (LYPLAL1) with an IC50 of 0.006 μM. LYPLAL1-IN-1 increases glucose production.
    LYPLAL1-IN-1
  • HY-153559
    Lp-PLA2-IN-13
    		Inhibitor
    Lp-PLA2-IN-13 (compound 15) is a potent Lp-PLA2 inhibitor. Lp-PLA2-IN-13 has the potential for the research of neurodegenerative related diseases.
    Lp-PLA2-IN-13
  • HY-D1584
    C12 NBD Sphingomyelin
    		≥99.0%
    C12 NBD sphingomyelin is an active derivative of sphingomyelin (HY-113498) that is tagged with fluorescent C12 nitrobenzoxadiazole (C12 NBD). C12 NBD sphingomyelin can be used as a sphingomyelinase substrate for studying the metabolism and transport of sphingomyelins (Ex=470 nm, Em=525 nm).
    C12 NBD Sphingomyelin
  • HY-125986
    GK187
    		Inhibitor ≥98.0%
    GK187 is a potent and selective Group VIA calcium-independent phospholipase A2 (GVIA iPLA2) inhibitor with an XI(50) value of 0.0001. GK187 can be used for researching various neurological disorders.
    [The XI(50) is the mole fraction of the inhibitor in the total substrate interface required to inhibit the enzyme by 50%.]
    GK187
  • HY-70083
    SPK-601
    		Inhibitor 98.46%
    SPK-601 (LMV-601) is an inhibitor of the phosphatidylcholine-specific phospholipase C (PC-PLC). SPK-601 also can be used as an antimicrobial agent.
    SPK-601
  • HY-B0113R
    Omeprazole (Standard)
    		Inhibitor 99.86%
    Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    Omeprazole (Standard)
  • HY-19151
    Fuzapladib
    		Inhibitor 98.75%
    Fuzapladib (IS-741), an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site.
    Fuzapladib
  • HY-108609
    YM-26734
    		Inhibitor
    YM-26734 is a competitive inhibitor of secretory phospholipase A2 (PLA2) that exhibits a broad inhibitory profile to several PLA2s.
    YM-26734
  • HY-155111
    nSMase2-IN-1
    		98.24%
    nSMase2-IN-1 is an orally active Neutral sphingomyelinase 2 (nSMase2) inhibitor with an IC50 value of 0.13 ± 0.06 μM. nSMase2-IN-1 is metabolically stable in liver microsomes and orally available with a favorable brain-to-plasma ratio. nSMase2-IN-1 can be used for nervous system disease research.
    nSMase2-IN-1
  • HY-W612338
    9-Oxononanoic acid
    		Activator
    9-Oxononanoic acid (9-ONA) is secondary reaction product of lipid peroxidation. 9-Oxononanoic acid induces phospholipase A2 (PLA2) activity and thromboxane A2 (HY-113350) production (TXA2). 9-Oxononanoic acid induces the platelet aggregation in human blood. 9-Oxononanoic acid is orally active.
    9-Oxononanoic acid
  • HY-129944A
    MJ33-OH lithium
    		Inhibitor
    MJ33-OH lithium is a metabolite of MJ33. MJ33 is an active-site-directed, specific, competitive, and reversible phospholipase A2 (PLA2) inhibitor. MJ33 blocks the calcium-independent phospholipase A2 (iPLA2) activity of Prdx6.
    MJ33-OH lithium
  • HY-108616
    VU 0364739 hydrochloride
    		Inhibitor
    VU 0364739 hydrochloride is a highly selective phospholipase D2 (PLD2) inhibitor with IC50s of 20 and 1500 nM for PLD2 and PLD1, respectively. VU 0364739 hydrochloride induces apoptosis and it can be used for cancer research.
    VU 0364739 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity
Phospholipase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.